Alogliptin safe but aleglitazar flops

The anti-diabetes therapy alogliptin does not increase cardiovascular mortality or heart failure in patients with recent acute coronary syndrome, according to new data.

Presented Saturday at the annual meeting of the American College of Cardiology in Washington, a sub-analysis of the EXAMINE trial showed similar rates of CV mortality in type 2 diabetes patients with recent acute coronary syndrome taking alogliptin compared with placebo.